|Advances in Translational Medicine of Breast Cancer: From Bench to Bedside
|Department of Medical Oncology, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, 210009, China
| 1 Song M, Lee HW, Kang D. The potential application of personalized preventive research. Jpn J Clin Oncol, 2014, 44(11): 1017-24.
2 Vici P, Pizzuti L, Natoli C, et al. Triple positive breast cancer: A distinct subtype? Cancer Treat Rev, 2015, 41(2): 69-76.
3 Ravikumar G, Ananthamurthy A. Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters. J Cancer Res Ther, 2014, 10(3): 671-5.
4 Liu Q, Boudot A, Ni J, et al. Cyclin D1 and C/EBPβ LAP1 operate in a common pathway to promote mammary epithelial cell differentiation. Mol Cell Biol, 2014, 34(16): 3168-79.
5 Zhang L, Zeng M, Tian L, et al. Cyclin D1, Ki-67 and PTEN expression and significance in breast cancer. Journal of Modern Oncology, 2013, 21(8): 1772-4.
6 Naidu R, Wahab NA, Yadav M, et al. Protein expression and molecular analysis of c-mycgene in primary breast carcinomas usingimmunohistochemistry and differential polymerase chain reaction. Int J Mol Med, 2002, 9(2): 189-96.
7 Li Z, Meng Q, Yu Q, et al. Evaluation of c-myc and CCNE2 amplification in breast cancer with quantitative multi-gene fluorescence in-situ hybridization. Chinese J Pathol, 2014, 43(7): 455-8.
8 Rummukainen JK, Salminen T, Lundin J, et al. Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancertissue array samples. Lab Invest, 2001, 81(11): 1545-51.
9 Liu J, Esmailpour T, Shang X, et al. TBX3 over-expression causes mammary gland hyperplasia and increases mammary stem-like cells in aninducible transgenic mouse model.
BMC Dev Biol, 2011, 11: 65.
10 Douglas NC, Papaioannou VE. The T-box transcription factors TBX2 and TBX3 in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia, 2013, 18(2): 143-7.
11 Economopoulou P, Dimitriadis G, Psyrri A. Beyond BRCA: new hereditary breast cancer susceptibility genes. Cancer Treat Rev, 2015, 41(1): 1-8.
12 Maillet P, Chappuis PO, Khoshbeen-Boudal M, et al. Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families. Cancer Genet Cytogenet, 2006, 169(1): 62-8.
13 Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ, 2014, 348: g226.
14 Kechagioglou P, Papi RM, Provatopoulou X, et al. Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression. Anticancer Res, 2014, 34(3): 1387-400.
15 Migliaccio I, Di Leo A, Malorni L. Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. Curr Opin Oncol, 2014, 26(6): 568-75.
16 Xiang H, Li H, Ge W, et al. Association of CDKN1B gene polymorphisms with susceptibility to breast cancer: a metaanalysis. Mol Biol Rep, 2013, 40(11): 6371-7.
17 Zhao J, Liu H, Wang M, et al. Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Surg Oncol, 2009, 100(2): 89-94.
18 Nishimura R, Osako T, Okumura Y, et al. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp
Ther Med, 2010, 1(5): 747-54.
19 Wiechmann L, Sampson M, Stempel M, et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol, 2009, 16(10): 2705-10.
20 Kapp AV, Jeffrey SS, Langerød A, et al. Discovery and validation of breast cancer subtypes. BMC Genomics, 2006, 7: 231.
21 Zhang Z, Zhao L, Guo H, et al. HER-2 overexpression and gene amplification of advanced breast cancers determined by fluorescence in situ hybridization in fine needle aspiration specimens. Chinese J of Oncol, 2014, 36(3): 183-7.
22 Wang G, Zhang W, Jiang W, et al. Overexpression of her-2 associated with the progression of esophageal cancer patients. Hepatogastroenterology, 2013, 60(128): 1972-8.
23 Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res, 2007, 13(8): 2329-34.
24 Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol, 2010,
25 Limentani SA, Brufsky AM, Erban JK, et al. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvantdoxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressinglocally advanced breast cancer. J Clin Oncol, 2007, 25(10): 1232-8.
26 Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med, 2015, 372(2): 134-41.
27 Bouchalova K, Svoboda M, Kharaishvili G, et al. BCL2 is an independent predictor of outcome in basal-like triplenegative breast cancers treated with adjuvant anthracyclinebased chemotherapy. Tumour Biol, 2015, [Epub ahead of print].
28 Lien MY, Liu LC, Wang HC, et al. Safety and efficacy of pegylated liposomal doxorubicinbased adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer. Anticancer Res, 2014, 34(12): 7319-26.
29 Zhang L, Fang C, Xu X, et al. Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis. Biomed Res Int, 2015, 2015: 357485.
30 Wong-Brown MW, Meldrum CJ, Carpenter JE, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat, 2015, 150(1): 71-80.
31 Bellizzi A, Greco MR, Rubino R, et al. The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells. Int J Oncol, 2015, 46(3): 1214-24.
32 Xu L, Zhang GP, Xie XD. A meta-analysis of efficacy and safety of chemotherapy combined with bevacizumab for breast cancer with negative Her-2. Chinese J Evid-Based Med, 2012, 12(11): 1347-53.
33 De Abreu FB, Wells WA, Tsongalis GJ. The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine. Am J Pathol, 2013, 183(4): 1075-83.
34 Hardesty LA. Issues to consider before implementing digital breast tomosynthesis into a breast imaging practice. AJR Am J Roentgenol, 2015, 204(3): 681-4.
35 O’Connor MK. Molecular breast imaging: an emerging modality for breast cancer screening. Breast Cancer Manag, 2015, 4(1): 33-40.
36 Pettersson A, Graff RE, Ursin G, et al. Mammographic density phenotypes and risk of breast cancer: a metaanalysis. J Natl Cancer Inst, 2014, 106(5). pii: dju078.
37 John EM, McGuire V, Thomas D, et al. Diagnostic chest X-rays and breast cancer risk before age 50 years for BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev, 2013, 22(9): 1547-56.
38 Frankenberg-Schwager M, Gregus A. Chromosomal instability induced by mammography X-rays in primary human fibroblasts from BRCA1 and BRCA2 mutation carriers. Int J Radiat Biol, 2012, 88(11): 846-57.
39 Jiang L, Ma T, Moran MS, et al. Mammographic features are associated with clinicopathological characteristics in invasive breast cancer. Anticancer Res, 2011, 31(6): 2327-34.
40 Sun SS, Zhang B, Zhao HM, et al. Association between mammographic features and clinicopathological characteristics in invasive ductal carcinoma of breast cancer.
Mol Clin Oncol, 2015, 3(1): 623-9.
41 Obdeijn IM, Winter-Warnars GA, Mann RM, et al. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study. Breast Cancer Res Treat, 2014, 144(3): 577-82.
||TAN Mi-duo. Research Progress of Translational Medicine in Breast Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 86-91.
||Lukas Gietz, Benjamin Mayer. A Resampling Approach for Sample Size Estimation in Animal Experiments[J]. Journal of International Translational Medicine, 2017, 5(2): 53-62.
||QIAN Ting, HUANG Xin-en. Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 63-66.
||MAO Xiao-dong, ZHE Yi, CHEN Ya-jun, LIU Kang-sheng. Detection of Serum Anti-Müllerian Hormone Level for Women of Reproductive Age: A Cross-Sectional Study[J]. Journal of International Translational Medicine, 2017, 5(2): 67-70.
||LIU Yong-jun, ZHOU Yan. Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy[J]. Journal of International Translational Medicine, 2017, 5(2): 80-85.
||WANG Peng. Chimeric Antigen Receptor-Engineered T Cells in Tumor Immunotherapy: From Bench to Beside[J]. Journal of International Translational Medicine, 2017, 5(2): 92-97.